Drug Interaction study between AZD3480 and aripiprazole in healthy subjects
Study identifier:D3691C00001
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
Study Complete
Official Title
A single-centre, double-blind, randomised, parallel group study of repeated oral doses of AZD3480/placebo and a single dose of aripiprazole to evaluate the pharmacokinetic interaction between AZD3480 and aripiprazole in healthy subjects (phase I)
Medical condition
Alzheimer's disease
Phase
Phase 1
Healthy volunteers
Yes
Study drug
AZD3480, Placebo, Aripiprazole
Sex
Male
Actual Enrollment
52
Study type
Interventional
Age
18 Years - 45 Years
Date
Study Start Date: 01 Mar 2008
Primary Completion Date: 01 Apr 2009
Study Completion Date: 01 Apr 2009
Study design
Allocation: Randomized
Endpoint Classification: Pharmacokinetics Study
Intervention Model: Parallel Assignment
Masking: Double Blind
Primary Purpose: Basic Science
Verification:
Verified 01 Jul 2014 by AstraZeneca Pharmaceuticals
Sponsors
AstraZeneca Pharmaceuticals
Collaborators
-
Inclusion and exclusion criteria
Loading...
No locations available
| Arms | Assigned Interventions |
|---|---|
| Experimental: 1 AZD3480 + Aripiprazole | Drug: AZD3480 AZD3480 capsules qd, oral, 22 days Drug: Aripiprazole single dose on day 5 Other Name: Abilify |
| Experimental: 2 Placebo + Aripiprazole | Drug: Placebo Placebo qd, 12 days Drug: Aripiprazole single dose on day 5 Other Name: Abilify |
Contacts
Investigators
Principal Investigator
Lennart Jeppsson
AstraZeneca R&D, Södertälje, Sweden
